Filing Details
- Accession Number:
- 0001127602-16-062200
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-09-08 13:35:23
- Reporting Period:
- 2016-09-06
- Filing Date:
- 2016-09-08
- Accepted Time:
- 2016-09-08 13:35:23
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
882095 | Gilead Sciences Inc | GILD | Biological Products, (No Disgnostic Substances) (2836) | 943047598 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1191589 | F John Milligan | Gilead Sciences, Inc. 333 Lakeside Drive Foster City CA 94404 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2016-09-06 | 70,000 | $20.74 | 1,128,963 | No | 4 | M | Direct | |
Common Stock | Disposition | 2016-09-06 | 70,000 | $77.74 | 1,058,963 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Non-qualified Stock Option (Right to Buy) | Disposition | 2016-09-06 | 70,000 | $0.00 | 70,000 | $20.74 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2017-05-08 | No | 4 | M | Direct |
Footnotes
- The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
- Options vest over a five year period beginning 5/08/2008, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, ending on 5/08/2012.
- Sale prices reported for the transactions reported here range from $77.265 to $77.99. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.